FDA Clears Candela's Ellipse I2PL System for Skin Rejuvenation; Next Generation I2PL Technology Provides Superior Results

WAYLAND,Mass.--()--Feb. 28, 2005--Candela Corporation (NASDAQ: CLZR) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its next generation Ellipse I2PL system for skin rejuvenation of vascular and pigmented abnormalities. Candela is distributing the Ellipse I2PL in the U.S. through a partnership with Danish Dermatologic Development A/S (DDD).

The Ellipse successfully treats sun-damaged skin to reduce pigment and vascular disturbances by specifically heating targeted structures in the skin. It has a lightweight, ergonomically shaped hand piece that is easy to use and comfortable for both clients and operators. The Ellipse allows effective treatments of large or small body areas and is the only intense pulsed light system to feature patented I2PL technology, which reduces the risk of side effects to the surrounding skin.

Candela recently unveiled the Ellipse I2PL at the American Academy of Dermatology (AAD) 63rd Annual Meeting. "We are very excited about the high level of interest we received from attendees at the AAD," said Gerard E. Puorro, Candela's President and Chief Executive Officer. "The enthusiasm expressed at the meeting is a good indicator that the Ellipse I2PL will be in high demand and we look forward to being able to provide our customers with the best treatment available for skin rejuvenation," Puorro added.

As a leader in the aesthetic device industry, Candela continues to offer high-quality products and programs to best meet customer requirements. "Skin rejuvenation is one of the most popular treatments for IPL systems on the market," said Dennis Herman, Candela's Senior Vice President of North American Sales, Marketing & Service. Herman continued, "With the FDA clearance, we can now offer our customers a complete package to meet the specific clinical applications they are interested in treating."

About Candela:

Candela Corporation, an ISO-9001 certified company, develops, manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 64 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 16 years ago, and currently has an installed base of 8,000 lasers worldwide. Candela is an Equal Opportunity and Affirmative Action Employer (Male/Female/Handicapped/Veteran). Visit Candela on the Web at http://www.candelalaser.com.

Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC, including but not limited to, Candela's Annual Report on Form 10-K for the year ended July 3, 2004, and subsequent Quarterly Reports on Form 10-Q. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.

Contacts

Candela Corporation
Jane Smith, 508-358-7637, ext. 247
Jane.smith@candelalaser.com

Contacts

Candela Corporation
Jane Smith, 508-358-7637, ext. 247
Jane.smith@candelalaser.com